Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
Shares of synthetic biology conglomerate Intrexon (NYSE: XON) were crushed following the release of third-quarter 2017 earnings last week. Although missing Wall Street's revenue expectations played a role in the 26% decline during the next trading day, there were several other factors at play.
Vague discussions of important healthcare programs heading to the clinic, the loss of one of the few blue-chip partners, the end of an important financial arrangement, and delays in the gas-to-chemicals platform were likely contributing factors for the stock's drop as well. The operational trajectory of the self-proclaimed synthetic biology leader does appear to be making analysts increasingly skittish. Here's what investors need to know.
Image source: Getty Images.
Source: Fool.com
